0
0This research article from Nature Medicine examines how different brain cells react to amyloid-β (Aβ) and tau proteins to determine Alzheimer's disease progression or cognitive resilience. By analyzing brain tissue from octogenarians and centenarians, the authors identified a critical immune inflection point where microglial activity shifts from an early inflammatory response to a late-stage antigen-presenting state. The study reveals that cognitive resilience follows two distinct paths: some elderly individuals avoid the late-stage microglial program entirely, while others activate it but successfully resist the subsequent accumulation of toxic tau. These findings suggest that the transition between microglial states is a key factor in determining whether a patient develops dementia. Ultimately, the researchers propose that targeting these cellular pathways could offer new therapeutic strategies for maintaining brain health during aging.
References:
Lu A, Chen W T, Dalby M, et al. Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience[J]. Nature Medicine, 2026: 1-13.
